Tofacitinib for managing granuloma formation after dermal filler injection: three case reports and literature review.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: Houndmills, Basingstoke, Hampshire, UK : M. Dunitz and Macmillan Press, [c1989]-

Dermal Fillers* ; Janus Kinase Inhibitors*/therapeutic use ; Skin Diseases*/drug therapy ; Piperidines* ; Pyrimidines*; Humans ; Janus Kinases ; Signal Transduction ; STAT Transcription Factors ; Granuloma/chemically induced ; Granuloma/drug therapy

Background: Granuloma formation is an uncommon and persistent skin inflammatory condition caused by the injection of dermal fillers. The exact cause of this reaction is not well understood, but it may be associated with irritating components or abnormal immune function. Treating granulomas can be difficult. However, recent research has shown that Janus kinase (JAK) inhibitors hold promise as a potential therapy for refractory granulomatous diseases.
Objectives: The aim was to evaluate the efficacy and safety of tofacitinib as a treatment for granulomas secondary to filler injection and the possible mechanisms were discussed and summarized.
Methods: This study focuses on three cases of patients who experienced granuloma formation after receiving filler injections and were subsequently treated with tofacitinib. The efficacy and safety of the treatment were evaluated using parameters such as photographs and monitoring for any adverse reactions. In addition, a literature review was conducted to explore the underlying mechanisms and potential effects of tofacitinib.
Results: All three cases recovered from swelling and nodules without side effects through the off-label use of oral tofacitinib. Existing data review reveals some approaches for cutaneous granulomatous disorders like inhibiting macrophage activation and downregulation of the JAK-STAT pathway.
Conclusion: This report emphasizes the effectiveness of JAK inhibitors in treating granulomas caused by filler injections. Recent advancements in understanding the underlying mechanisms of granulomatous reactions have paved the way for JAK inhibitors to be regarded as a promising treatment choice. However, further research is necessary to fully assess the safety and long-term effectiveness of using tofacitinib for granuloma treatment.

Keywords: Filler; granuloma; tofacitinib; treatment

87LA6FU830 (tofacitinib)
0 (Dermal Fillers)
0 (Janus Kinase Inhibitors)
EC 2.7.10.2 (Janus Kinases)
0 (STAT Transcription Factors)
0 (Piperidines)
0 (Pyrimidines)

Date Created: 20240418 Date Completed: 20240419 Latest Revision: 20240419

20240419

10.1080/09546634.2024.2338281

38632962